Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

NCT06020014 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06020014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06020014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 16, 2023
Completion date
October 28, 2025
Enrollment
339 (actual)
Sites
124

Conditions

As the registry lists them; a condition with its own page is linked.

asthma